The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients
This trial has been completed.
|Conditions||coronary artery bypass grafting, heart diseases, heart valve diseases|
|Sponsor||Weill Medical College of Cornell University|
|Start date||January 1999|
|End date||December 2006|
|Trial size||50 participants|
|Trial identifier||NCT00226265, 1203-069|
The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.
All participants from 18 years up to 100 years old.
Inclusion Criteria: - Cardiac surgery patients who are between the ages of 18 and 100 - Are English speaking - Able to give consent - Undergoing cardiac surgery including (but not limited to): - Aortic valve replacement (AVR) - Mitral valve replacement (MVR) - Tricuspid valve replacement (TVR) - Coronary artery bypass graft (CABG). Exclusion Criteria: - Non-cardiac surgery patients
|Official title||The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients|
|Principal investigator||Mary E Charlson, MD|
|Description||The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.|
Call for more information